Literature DB >> 10713720

Complement mediated cell death is associated with DNA fragmentation.

M S Cragg1, W J Howatt, L Bloodworth, V A Anderson, B P Morgan, M J Glennie.   

Abstract

In this study, we demonstrate for the first time that complement attack of target cells, in the presence of suitably high levels of serum, can induce the oligonucleosomal DNA fragmentation characteristic of apoptosis. This phenomenon requires membrane permeabilisation induced by formation of the complete membrane attack complex and relies on physiologically relevant levels of serum. TUNEL analysis detected complement mediated DNA fragmentation as early as 30 min after the addition of serum and electron microscopy confirmed that chromatin became condensed after complement attack. Various experiments implicate serum DNase I as the mediator of this DNA fragmentation. Intriguingly, membrane permeability induced by melittin gave rise to similar serum dependent DNA fragmentation. The implications of these results for the study of apoptosis in vitro and in vivo are discussed.

Mesh:

Substances:

Year:  2000        PMID: 10713720     DOI: 10.1038/sj.cdd.4400627

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  16 in total

Review 1.  The role of the complement system in innate immunity.

Authors:  Horea Rus; Cornelia Cudrici; Florin Niculescu
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 2.  Membrane attack by complement: the assembly and biology of terminal complement complexes.

Authors:  Cosmin A Tegla; Cornelia Cudrici; Snehal Patel; Richard Trippe; Violeta Rus; Florin Niculescu; Horea Rus
Journal:  Immunol Res       Date:  2011-10       Impact factor: 2.829

3.  C5b-9-activated, K(v)1.3 channels mediate oligodendrocyte cell cycle activation and dedifferentiation.

Authors:  Cosmin A Tegla; Cornelia Cudrici; Monika Rozycka; Katerina Soloviova; Takahiro Ito; Anil K Singh; Aamer Khan; Philippe Azimzadeh; Maria Andrian-Albescu; Anver Khan; Florin Niculescu; Violeta Rus; Susan I V Judge; Horea Rus
Journal:  Exp Mol Pathol       Date:  2011-04-22       Impact factor: 3.362

4.  Decreased membrane complement regulators in the retinal pigmented epithelium contributes to age-related macular degeneration.

Authors:  Katayoon B Ebrahimi; Natalia Fijalkowski; Marisol Cano; James T Handa
Journal:  J Pathol       Date:  2013-01-24       Impact factor: 7.996

5.  Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo.

Authors:  Yi-Fan Hsu; Daniel Ajona; Leticia Corrales; Jose M Lopez-Picazo; Alfonso Gurpide; Luis M Montuenga; Ruben Pio
Journal:  Mol Cancer       Date:  2010-06-07       Impact factor: 27.401

6.  Complement C5 regulates the expression of insulin-like growth factor binding proteins in chronic experimental allergic encephalomyelitis.

Authors:  Cornelia Cudrici; Takahiro Ito; Ekaterina Zafranskaia; Susanna Weerth; Violeta Rus; Hegang Chen; Florin Niculescu; Katerina Soloviova; Cosmin Tegla; Adrian Gherman; Cedric S Raine; Moon L Shin; Horea Rus
Journal:  J Neuroimmunol       Date:  2008-10-15       Impact factor: 3.478

7.  Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab.

Authors:  Srinivas Mamidi; Marc Cinci; Max Hasmann; Volker Fehring; Michael Kirschfink
Journal:  Mol Oncol       Date:  2013-02-20       Impact factor: 6.603

8.  Lysophosphatidic acid prevents renal ischemia-reperfusion injury by inhibition of apoptosis and complement activation.

Authors:  Bart de Vries; Robert A Matthijsen; Annemarie A J H M van Bijnen; Tim G A M Wolfs; Wim A Buurman
Journal:  Am J Pathol       Date:  2003-07       Impact factor: 4.307

9.  Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic.

Authors:  Mark S Cragg; Elisa S Jansen; Michele Cook; Claire Harris; Andreas Strasser; Clare L Scott
Journal:  J Clin Invest       Date:  2008-10-23       Impact factor: 14.808

10.  BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression.

Authors:  Thomas E C Cummin; Kerry L Cox; Tom D Murray; Anna H Turaj; Lisa Dunning; Vikki L English; Rachel Fell; Graham Packham; Yan Ma; Ben Powell; Peter W M Johnson; Mark S Cragg; Matthew J Carter
Journal:  Blood Adv       Date:  2020-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.